- Subscribe
- Log In More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
- Basket
- Search More
Advanced search
- Latest content
- Current issue
- Archive
- Authors
- About
- Podcasts
Advanced search
- CloseMore
Main menu
- Latest content
- Current issue
- Archive
- Authors
- About
- Podcasts
See AlsoOP0053 THE EFFECTS OF RITUXIMAB ON QUALITY OF LIFE, PAIN AND MOBILITY SCORES IN THE PRECLINICAL PHASE OF RHEUMATOID ARTHRITIS: 2 YEAR DATA FROM THE PRAIRI STUDYAB0491 EFFICACY OF GUSELKUMAB IN EARLY-ONSET AND LATE-ONSET PSORIATIC ARTHRITIS: POST HOC POOLED ANALYSES OF TWO PHASE 3 RANDOMIZED CONTROLLED TRIALS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITISOP0143-HPR EFFECTIVENESS OF LONGSTANDING EXERCISE THERAPY VERSUS USUAL CARE IN PEOPLE WITH AXIAL SPONDYLOARTHRITIS AND SEVERE FUNCTIONAL LIMITATIONS: A RANDOMIZED CONTROLLED TRIAL (L-EXSPA)AB0369 COMPARISON OF GAIT ANALYSIS, QUALITY OF LIFE AND FUNCTIONAL OUTCOME IN PATIENTS WITH TOTAL KNEE ARTHROPLASTY AND HEALTHY ADULTS - Subscribe
- Log in More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
- BMJ Journals
You are here
- Home
- Archive
- Volume 83,Issue Suppl 1
- POS0943 GUSELKUMAB PROVIDES DURABLE IMPROVEMENTS IN PAIN AMONG PATIENTS WITH PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TNFi: COSMOS PHASE 3b TRIAL
Email alerts
Article Text
Article menu
- Article Text
- Article info
- Citation Tools
- Share
- Rapid Responses
- Article metrics
- Alerts
Scientific Abstracts
Poster View
Pain in rheumatic diseases, including fibromyalgia
POS0943 GUSELKUMAB PROVIDES DURABLE IMPROVEMENTS IN PAIN AMONG PATIENTS WITH PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TNFi: COSMOS PHASE 3b TRIAL
- L. C. Coates1,
- G. Schett2,
- M. A. D’agostino3,
- J. Ramírez4,
- M. Sharaf5,
- E. Rampakakis6,7,
- M. Koivunen8,
- M. Zimmermann9,
- F. Lavie10,
- P. S. Helliwell11
- 1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
- 2University of Erlangen, Department of Medicine 3 – Rheumatology and Immunology, Erlangen, Germany
- 3Department of Geriatrics and Orthopaedic Sciences, Università Cattolica del Sacro Cuore, Rome, Italy
- 4Rheumatology Department, Hospital Clínic, Barcelona, Spain, Barcelona, Spain
- 5Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates
- 6McGill University, Department of Pediatrics, Montreal, QC, Canada
- 7JSS Medical Research Inc., Scientific Affairs, Montreal, QC, Canada
- 8Janssen Cilag Oy, Espoo, Finland
- 9Janssen Medical Affairs, LLC, Zug, Switzerland
- 10The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France
- 11Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Abstract
Background: Patients (pts) with psoriatic arthritis (PsA) report pain relief as a priority for treatment.[1] In prior analyses of a predominately bio-naïve population, guselkumab (GUS; an interleukin [IL]-23 inhibitor) treatment led to an early and significant improvement in pain at Week (W)2 vs placebo (PBO).[2] The pain response was sustained at 1 year.[2]
Objectives: Using data from the COSMOS trial (NCT03796858), we sought to compare the effect of GUS vs PBO on pain assessed by several measures, and to evaluate the time course of pain improvement in pts with PsA and inadequate response to 1 or 2 tumour necrosis factor inhibitors (TNFi-IR).
Methods: Adults with active PsA (swollen/tender joint counts [SJC/TJC], each ≥3) and TNFi-IR were randomized 2:1 to receive subcutaneous GUS 100 mg (n=189) or PBO (n=96) at W0, W4, then every 8 weeks thereafter. PBO pts crossed over to GUS at W16 (early escape [EE], n=45) or W24 (planned, n=51). In this post hoc analysis, through W24, pts with missing data or those who met treatment failure rules, including EE criteria, were imputed as non-responders. Through W24, least squares mean changes from baseline (BL) in pain measured via a visual analogue scale (VAS; 0–100 mm [lower score = less = pain]), the bodily pain domain of the 36-Item Short Form Health Survey (0–100 [higher score = less pain]), and investigator-assessed TJC (0–68 [lower score = less pain]) were estimated using a mixed-effects model for repeated measures, which included prior number of TNFi, BL use of conventional systemic disease-modifying antirheumatic drugs (csDMARDs), and BL pain score of the respective outcome as explanatory variables. The proportions of pts achieving minimal clinically important improvements in binary endpoints (≥15 mm on the pain VAS)[3] and clinically meaningful/substantial improvement (≥30/≥50% on the pain VAS)[3] through W24 are also described. Maintenance of pain response at W48 was assessed among pts who achieved response at W24, using as-observed data. Kaplan–Meier (KM) and Cox regression (adjusted for prior number of TNFi, and BL use of csDMARDs, and pain score) analyses were used to assess time to achievement of each binary endpoint through W24. All P values are nominal.
Results: Among GUS- and PBO-randomized pts, mean BL values for pain VAS, bodily pain, and TJC were 64.6/60.3, 34.9/35.9, and 21.0/18.2, respectively. Numerically greater reductions in scores were observed with GUS vs PBO by the first timepoint assessed (W4), reaching statistical significance at W8 for TJC, W12 for pain VAS, and W16 for bodily pain (Figure 1).
In the KM analyses, separation of GUS and PBO groups for meaningful pain improvement (≥15 mm and ≥30% improvement in pain VAS) occurred by the first assessment timepoint (Figure 2). The median number of weeks to achieve a ≥15 mm, ≥20%, and ≥30% improvement in pain VAS with GUS was 8, 8, and 12, respectively. A Cox regression analysis, adjusted for potential confounders, yielded consistent results.
Of the GUS-randomized pts, response rates at W24 and W48 for a ≥15 mm, ≥30%, and ≥50% improvement in pain VAS were 47.6/61.4%, 42.3/58.7%, and 23.8/49.2%, respectively. Among pts who achieved ≥15 mm (n=104), ≥30% (n=92), and ≥50 (n=50) improvement in pain VAS at W24, 91.3%, 91.3%, and 88.0% of pts, respectively, maintained response at W48.
Conclusion: In TNFi-IR PsA pts with a high burden of disease activity and substantial pain, early separation in pain response was observed between GUS- and PBO-treated groups, with a significantly higher proportion of GUS-randomized pts achieving meaningful improvements in pain. These findings are consistent with those observed in a large population of predominately bio-naïve pts.[2] Among pts who achieved pain endpoints at W24, ≥88% maintained response at W48, suggesting durable improvements in pain, even in a TNFi-IR PsA pt population.
REFERENCES: [1] Gudu T et al. Expert Rev Clin Immunol 2018;14:405–17
[2] Nash P et al. Presented at EULAR congress, 1–4 June 2022, Copenhagen, Denmark. Poster 1070
[3] Dworkin RH et al. J Pain 2008;9:105–21
[4] Leung YY et al. J Rheumatol 2011;38:2077–9
- Download figure
- Open in new tab
- Download powerpoint
- Download figure
- Open in new tab
- Download powerpoint
Acknowledgements: NIL.
Disclosure of Interests: Laura C. Coates has received speakers fees and/or consulting fees and/or research grants from: AbbVie, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen-Cilag GmbH, Medac, Moonlake, Novartis, Pfizer, and UCB Pharma, has received speakers fees and/or consulting fees and/or research grants from: AbbVie, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen-Cilag GmbH, Medac, Moonlake, Novartis, Pfizer, and UCB Pharma, has received speakers fees and/or consulting fees and/or research grants from: AbbVie, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen-Cilag GmbH, Medac, Moonlake, Novartis, Pfizer, and UCB Pharma, Georg Schett: None declared, Maria Antonietta D’Agostino: None declared, Julio Ramírez has received speaker fees and/or instructor fees and/or consultant fees and/or research grants from: AbbVie, Amgen, Eli Lilly, Janssen-Cilag GmbH, Novartis, Pfizer, and UCB Pharma, has received speaker fees and/or instructor fees and/or consultant fees and/or research grants from: AbbVie, Amgen, Eli Lilly, Janssen-Cilag GmbH, Novartis, Pfizer, and UCB Pharma, has received speaker fees and/or instructor fees and/or consultant fees and/or research grants from: AbbVie, Amgen, Eli Lilly, Janssen-Cilag GmbH, Novartis, Pfizer, and UCB Pharma, has received speaker fees and/or instructor fees and/or consultant fees and/or research grants from: AbbVie, Amgen, Eli Lilly, Janssen-Cilag GmbH, Novartis, Pfizer, and UCB Pharma, Mohamed Sharaf is an employee of Janssen Pharmaceutical Companies of Johnson & Johnson and owns Johnson & Johnson stock, Emmanouil Rampakakis is an employee of JSS Medical Research, providing consulting services to Janssen-Cilag GmbH, Minni Koivunen is an employee of Janssen Pharmaceutical Companies of Johnson & Johnson and owns Johnson & Johnson stock and/or stock options, Miriam Zimmermann is an employee of Janssen Pharmaceutical Companies of Johnson & Johnson and owns Johnson & Johnson stock and/or stock options, Frédéric Lavie is an employee of Janssen Pharmaceutical Companies of Johnson & Johnson and owns Johnson & Johnson stock and/or stock options, Philip S Helliwell has received speaker and/or consulting fees from: AbbVie, Amgen, Eli Lilly; Novartis and Janssen-Cilag GmbH, has received speaker and/or consulting fees from: AbbVie, Amgen, Eli Lilly; Novartis and Janssen-Cilag GmbH.
- Patient Reported Outcome Measures
- Pain
- Randomized controlled trial
- biological DMARD
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
- Patient Reported Outcome Measures
- Pain
- Randomized controlled trial
- biological DMARD
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens
Log in using your username and password
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens